Optimization of lentiviral vector transduction into peripheral blood mononuclear cells in combination with the fibronectin fragment CH-296 stimulation

Journal of Biochemistry

Volumn 149, Issue 3, 2011, Pages 285-292

  Chono, Hideto ^a   Goto, Yumi ^a   Yamakawa, Satoko ^a   Tanaka, Shinya ^a   Tosaka, Yasuhiro ^a   Nukaya, Ikuei ^a   Mineno, Junichi ^a  

^a TAKARA BIO INC   (Japan)

Author keywords

adoptive T cell transfer therapy; gene transfer; lentiviral vector; recombinant human fibronectin fragment (CH 296); T cell stimulation

Indexed keywords

ANTIBODY; CD28 ANTIBODY; CD3 ANTIGEN; CH 296; FIBRONECTIN; HOMING RECEPTOR; LENTIVIRUS VECTOR; LYMPHOCYTE SURFACE MARKER; UNCLASSIFIED DRUG;

ARTICLE; CELL EXPANSION; CELL GROWTH; CONTROLLED STUDY; DNA MODIFICATION; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; ANTIGENS, CD3; FIBRONECTINS; FLOW CYTOMETRY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LENTIVIRUS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 79952285666     PISSN: 0021924X     EISSN: 17562651     Source Type: Journal    
DOI: 10.1093/jb/mvq135     Document Type: Article

References (30)

1. Yoder, M.C. and Williams, D.A. (1995) Matrix molecule interactions with hematopoietic stem cells. Exp. Hematol. 23, 961-967
2. Ruoslahti, E. (1988) Fibronectin and its receptors. Annu. Rev. Biochem. 57, 375-413
3. Hynes, R.O. (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69, 11-25
4. + T cell activation via the CS1 alternatively spliced domain of fibronectin. J. Exp. Med. 172, 1185-1192
5. Nojima, Y., Rothstein, D.M., Sugita, K., Schlossman, S.F., and Morimoto, C. (1992) Ligation of VLA-4 on T cells stimulates tyrosine phosphorylation of a 105-kD protein. J. Exp. Med. 175, 1045-1053
6. Sato, T., Tachibana, K., Nojima, Y., D'Avirro, N., and Morimoto, C. (1995) Role of the VLA-4 molecule in T cell costimulation. Identification of the tyrosine phosphorylation pattern induced by the ligation of VLA-4. J. Immunol. 155, 2938-2947
7. Kimizuka, F., Taguchi, Y., Ohdate, Y., Kawase, Y., Shimojo, T., Hashino, K., Kato, I., Sekiguchi, K., and Titani, K. (1991) Production and characterization of functional domains of human fibronectin expressed in Escherichia coli. J. Biochem. 110, 284-291
8. Yu, S.S., Nukaya, I., Enoki, T., Chatani, E., Kato, A., Goto, Y., Dan, K., Sasaki, M., Tomita, K., Tanabe, M., Chono, H., Mineno, J., and Kato, I. (2008) In vivo persistence of genetically modified T cells generated ex vivo using the fibronectin CH296 stimulation method. Cancer Gene Ther. 8, 508-516
9. + T cells. J. Clin. Invest. 115, 1616-1626
10. Ideno, M., Enoki, T., and Kato, I. (2007) Naive T-like cell populations are expandable ex vivo to large numbers in combination with RetroNectin® and CD3-specific antibody plus IL-2, and naïve T-like cells show superior recognizing ability of tumor antigen. The 13th annual meeting of Japan Society of Gene Therapy, June 30, 2007, Nagoya, Aichi. Japan Society of Gene Therapy: Shinjuku, Tokyo
11. June, C.H. (2007) Principles of adoptive T cell cancer therapy. J. Clin. Invest. 117, 1204-1212
12. Schumacher, T.N. (2002) T-cell-receptor gene therapy. Nat. Rev. Immunol. 2, 512-519
13. Okamoto, S., Mineno, J., Ikeda, H., Fujiwara, H., Yasukawa, M., Shiku, H., and Kato, I. (2009) Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res. 69, 9003-9011
14. Hombach, A., Heuser, C., and Abken, H. (2002) The recombinant T cell receptor strategy: insights into structure and function of recombinant immunoreceptors on the way towards an optimal receptor design for cellular immunotherapy. Curr. Gene Ther. 2, 211-226
15. Gattinoni, L., Powell, D.J. Jr, Rosenberg, S.A., and Restifo, N.P. (2006) Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6, 383-393
16. + T cells. J. Clin. Invest. 115, 1616-1626
17. Robbins, P.F., Dudley, M.E., Wunderlich, J., El-Gamil, M., Li, Y.F., Zhou, J., Huang, J., Powell, D.J. Jr, and Rosenberg, S.A. (2004) Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173, 7125-7130 (Pubitemid 39628146)
18. Huang, J., Khong, H.T., Dudley, M.E., El-Gamil, M., Li, Y.F., Rosenberg, S.A., and Robbins, P.F. (2005) Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J. Immunother. 28, 258-267 (Pubitemid 40593992)
19. Zhou, J., Shen, X., Huang, J., Hodes, R.J., Rosenberg, S.A., and Robbins, P.F. (2005) Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175, 7046-7052 (Pubitemid 41598952)
20. Chono, H., Yoshioka, H., Ueno, M., and Kato, I. (2001) Removal of inhibitory substances with recombinant fibronectin-CH-296 plates enhances the retroviral transduction efficiency of CD34(+)CD38(-) bone marrow cells. J. Biochem. 130, 331-334 (Pubitemid 32845685)
21. Yang, S., Rosenberg, S.A., and Morgan, R.A. (2008) Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells. J. Immunother. 31, 830-839
22. Cavalieri, S., Cazzaniga, S., Geuna, M., Magnani, Z., Bordignon, C., Naldini, L., and Bonini, C. (2003) Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood 102, 497-505 (Pubitemid 36841966)
23. Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Ponzoni, M., Bartholomae, C., Sergi Sergi, L., Benedicenti, F., Ambrosi, A., Di Serio, C., Doglioni, C., von Kalle, C., and Naldini, L. (2006) Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 24, 687-696
24. Levine, B.L., Humeau, L.M., Boyer, J., MacGregor, R.R., Rebello, T., Lu, X., Binder, G.K., Slepushkin, V., Lemiale, F., Mascola, J.R, Bushman, F.D., Dropulic, B., and June, C.H. (2006) Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl. Acad. Sci. USA 103, 17372-17377
25. Zack, J.A., Arrigo, S.J., Weitsman, S.R., Go, A.S., Haislip, A., and Chen, I.S. (1990) HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61, 213-222
26. Maurice, M., Verhoeyen, E., Salmon, P., Trono, D., Russell, S.J., and Cosset, F.-L. (2002) Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. Blood 99, 2342-2350 (Pubitemid 34525419)
27. Korin, Y.D. and Zack, J.A. (1998) Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J. Virol. 72, 3161-3168 (Pubitemid 28175559)
28. Korin, Y.D. and Zack, J.A. (1999) Nonproductive human immunodeficiency virus type 1 infection in nucleoside-treated G0 lymphocytes. J. Virol. 73, 6526-6532 (Pubitemid 29327833)
29. + T cells mediate superior antitumor immunity. Proc. Natl. Acad. Sci. USA 106, 17469-17474
30. Morgan, R.A., Dudley, M.E., Wunderlich, J.R., Hughes, M.S., Yang, J.C., Sherry, R.M., Royal, R.E., Topalian, S.L., Kammula, U.S., Restifo, N.P., Zheng, Z., Nahvi, A., de Vries, C.R., Rogers-Freezer, L.J., Mavroukakis, S.A., and Rosenberg, S.A. (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129 (Pubitemid 44547756)